methyl 2,4-dichloro-3,5-dinitrobenzoate | 67451-32-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2,4-dichloro-3,5-dinitrobenzoate
• CAS: 67451-32-5
• 化学式: C₈H₄Cl₂N₂O₆
• 分子量: 295.036
• InChiKey: USJCPSDQCYIWDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  118
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 2,4-dichloro-3,5-dinitrobenzoate 在 盐酸 、 铁粉 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2,4-Dichloro-3,5-bis-(ethoxyoxalyl-amino)-benzoic acid methyl ester
  参考文献：
  名称：

  N,N'-(phenylene)dioxamic acids and their esters as antiallergy agents

  摘要：

  A series of dialkyl N,N'-(m-phenylene)dioxamates was synthesized by treatment of the requisite m-phenylenediamines with an alkyloxalyl chloride in the presence of triethylamine. Hydrolysis with sodium hydroxide solution gave the corresponding N,N'-(m-phenylene)dioxamic acids. Several N,N'-(p-phenylene)dioxamic acids were synthesized also in the same manner starting with the requisite p-phenylenediamines. These compounds were tested in the rat passive cutaneous anaphylaxis (PCA) assay. When tested iv, activity was found in the N,N'-(m-phenylene) dioxamic acids up to 2500 times that shown by disodium cromoglycate [50% inhibition at 0.001 mg/kg for N,N'-(2-chloro-5-cyano-m-phenylene)dioxamic acid (compound 61)]. Oral activity was seen in this series of compounds with duration of activity up to 120 min. Oral activity was detected in diethyl N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate (compound 38) at levels of drug as low as 0.1 mg/kg.

  DOI：

  10.1021/jm00207a016
• 作为产物：
  描述：

  2,4-二氯苯甲酸 在 硫酸 、 硝酸 作用下， 反应 13.0h， 生成 methyl 2,4-dichloro-3,5-dinitrobenzoate
  参考文献：
  名称：

  Fathalla, Magda F.; Hamed, Ezzat A., Journal of Chemical Research, 2006, # 7, p. 413 - 416

  摘要：

  DOI：

文献信息

• Anti-viral and anti-cancer agents
  申请人：RADOPATH LIMITED

  公开号：EP0677292A1

  公开（公告）日：1995-10-18

  2-chloro-5-nitrobenzoic acid and various other chloro and nitro substitute benzoic acid derivatives are disclosed for administration in tablet or injectable solution form for the prophylaxis and therapy of neoplasm or viral infection. The active compounds have surprising efficacy in various treatment regimes and have particular application to HIV-infection and demonstrate various beneficial effects, including regression of lesions in HIV-related Kaposi's sarcoma.

  2-氯-5-硝基苯甲酸以及各种其他氯代和硝基取代的苯甲酸衍生物被披露用于以片剂或可注射溶液形式给药，用于预防和新生物或病毒感染的 治疗。这些活性化合物在各种治疗方案中显示出惊人的疗效，特别适用于HIV感染，并在HIV相关的卡波西肉瘤中显示出各种有益效果，包括病变的消退。
• Arylating medicaments
  申请人：Radopath Pharmaceuticals International Limited

  公开号：EP1016405A2

  公开（公告）日：2000-07-05

  Various arylating agents having activity in the treatment of cancer and viral infection are disclosed. The active compounds include an aromatic ring having at least one labile leaving group and at least one electrophilic group. Preferred active compounds include chlorobenzenesulphonic acids and optionally halogenated nitrobenzenc compounds. In an anti-viral context, the active compounds have efficacy against HIV infections.

  本研究公开了在治疗癌症和病毒感染方面具有活性的各种芳基化剂。这些活性化合物包括一个芳香环，芳香环上至少有一个易变离去基团和至少一个亲电基团。优选的活性化合物包括氯苯磺酸和可选的卤代硝基苯化合物。在抗病毒方面，活性化合物具有抗艾滋病毒感染的功效。
• [EN] ANTI-VIRAL AND ANTI-CANCER AGENTS<br/>[FR] AGENTS ANTIVIRAUX ET ANTICANCEREUX
  申请人：RADOPATH LIMITED

  公开号：WO1995024897A1

  公开（公告）日：1995-09-21

  (EN) 2-Chloro-5-nitrobenzoic acid and various other chloro and nitro substitute benzoic acid derivatives are disclosed for administration in tablet or injectable solution form for the prophylaxis and therapy of neoplasm or viral infection. The active compounds have surprising efficacy in various treatment regimes and have particular application to HIV-infection and demonstrate various beneficial effects, including regression of lesions in HIV-related Kaposi's sarcoma.(FR) L'invention se rapporte à l'acide 2-chloro-5-nitrobenzoïque et à divers autres dérivés de l'acide benzoïque à substitution chloro et nitro, ces acides étant administrés sous forme de comprimés ou de solutions injectables, pour la prophylaxie et la thérapie des néoplasmes ou des infections virales. Les composés actifs ont une étonnante efficacité dans divers schémas thérapeutiques et s'appliquent notamment aux infections dues au VIH et présentent divers effets bénéfiques, y compris la régression de lésions dans la maladie de Kaposi associée au VIH.

  2-氯基-5-硝基苯zoic酸及若干其他氯基与硝基取代苯zoic酸衍生物的结构及其药理活性。这些化合物用于预防或治疗癌症或病毒性感染的载体性强的片剂或注射液。它对诊断治疗进行了表述，并提供不同方案和特定应用效果。 比如证明那些与黄体生成素相关的问题，以及HIV感染。文中还对HIV相关KaHi比率癌的各种良好效果进行表述，包括所有不同类型的病斑的缓解情况。
• Fathalla, Magda F.; Kassem, Taher S.; Hamed, Ezzat A., Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical and Analytical, 2008, vol. 47, # 9, p. 1348 - 1354
  作者：Fathalla, Magda F.、Kassem, Taher S.、Hamed, Ezzat A.

  DOI：——

  日期：——
• ARYLATING MEDICAMENTS
  申请人：RADOPATH LIMITED

  公开号：EP0700287A1

  公开（公告）日：1996-03-13